While prosthetic legs have undergone remarkable advances in the past decades, the typical prosthetic arm hasn’t changed much since World War II: an artificial limb with a hook on the end. It’s a less than thrilling prospect for U.S. soldiers returning from Iraq or Afghanistan with amputated arms.
The economic climate may be grim, but biotech banker G. Steven Burrill is looking to the future. The CEO of Burrill and Co. plans to invest $1 billion into Minnesota’s Pine Island biotechnology project and a private equity/venture capital fund.
Big news at ORTHOCON, DeviceSpace reports. The New Jersey-based company, which develops devices that deliver therapeutics to bone, recently announced the appointment of a new CEO and the closing of $25 million in Series B funding.
As Baby Boomers age, the market for arthroplasty, or joint replacement, is expected to grow rapidly in the coming years. Disc Motion Technologies (DMT) of Boca Raton, FL, has pioneered the first total joint replacement technique for the lumbar spine.
Many patients are left humiliated and depressed because of the daily disruptions caused by urinary or fecal incontinence. Vermont company AugmentRX is developing incontinence solutions for the 200 million-plus people worldwide who suffer from this debilitating condition.
A new analysis of AstraZeneca’s cholesterol-lowering statin Crestor shows that the drug sharply reduces the risk of venous thromboembolism (VTE), a potentially fatal disorder in which blood clots can form in the legs and travel to the lungs.
A new experimental device to treat atrial fibrillation had mixed results in a recent study but still shows promise as a treatment option. The Watchman is the first device designed to permanently treat atrial fibrillation, a heart condition in which blood stagnates in a small pouch called the left atrial appendage.
Only 9 percent of U.S. hospitals use electronic medical records, according to a new survey. It’s a far cry from the comprehensive, high-tech environment supported by the Obama and Bush administrations.
Pathway Medical Technologies, Inc. recently announced that it has secured a $40 million Series D round of financing, reports DeviceSpace. Raising such a large amount of capital is a rare achievement for a medical device venture, particularly in today’s tough economic climate.
A new study by Abbott Laboratories found that their drug-coated stent, Xience V, is more effective in the long term than a competitor’s. According to the Wall Street Journal, the data showed that rates of major cardiovascular events plateaued at 6.4% in the second and third years after Xience was implanted.
Copyright © 2024 | WordPress Theme by MH Themes